Literature DB >> 20059950

The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt.

Futoshi Suizu1, Yosuke Hiramuki, Fumihiko Okumura, Mami Matsuda, Akiko J Okumura, Noriyuki Hirata, Masumi Narita, Takashi Kohno, Jun Yokota, Miyuki Bohgaki, Chikashi Obuse, Shigetsugu Hatakeyama, Toshiyuki Obata, Masayuki Noguchi.   

Abstract

The serine threonine kinase Akt is a core survival factor that underlies a variety of human diseases. Although regulatory phosphorylation and dephosphorylation have been well documented, the other posttranslational mechanisms that modulate Akt activity remain unclear. We show here that tetratricopeptide repeat domain 3 (TTC3) is an E3 ligase that interacts with Akt. TTC3 contains a canonical RING finger motif, a pair of tetratricopeptide motifs, a putative Akt phosphorylation site, and nuclear localization signals, and is encoded by a gene within the Down syndrome (DS) critical region on chromosome 21. TTC3 is an Akt-specific E3 ligase that binds to phosphorylated Akt and facilitates its ubiquitination and degradation within the nucleus. Moreover, DS cells exhibit elevated TTC3 expression, reduced phosphorylated Akt, and accumulation in the G(2)M phase, which can be reversed by TTC3 siRNA or Myr-Akt. Thus, interaction between TTC3 and Akt may contribute to the clinical symptoms of DS. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20059950     DOI: 10.1016/j.devcel.2009.09.007

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  65 in total

Review 1.  Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development.

Authors:  W-L Yang; X Zhang; H-K Lin
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Transformation by E1A oncoprotein involves ubiquitin-mediated proteolysis of the neuronal and tumor repressor REST in the nucleus.

Authors:  Hancheng Guan; Robert P Ricciardi
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

3.  Akt is negatively regulated by the MULAN E3 ligase.

Authors:  Seunghee Bae; Sun-Yong Kim; Jin Hyuk Jung; Yeongmin Yoon; Hwa Jun Cha; Hyunjin Lee; Karam Kim; Jongran Kim; In-Sook An; Jongdoo Kim; Hong-Duck Um; In-Chul Park; Su-Jae Lee; Seon Young Nam; Young-Woo Jin; Jae Ho Lee; Sungkwan An
Journal:  Cell Res       Date:  2012-03-13       Impact factor: 25.617

4.  Control of mTORC1 signaling by the Opitz syndrome protein MID1.

Authors:  Enbo Liu; Christine A Knutzen; Sybille Krauss; Susann Schweiger; Gary G Chiang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

5.  Proteasome inhibition-induced downregulation of Akt/GSK-3β pathway contributes to abnormality of tau in hippocampal slice.

Authors:  Min Xie; Ruihong Shi; Ying Pan; Tao Zeng; Qicai Chen; Shaohui Wang; Xiaomei Liao
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

6.  Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle.

Authors:  Guillermo Risso; Federico Pelisch; Berta Pozzi; Pablo Mammi; Matías Blaustein; Alejandro Colman-Lerner; Anabella Srebrow
Journal:  Cell Cycle       Date:  2013-08-27       Impact factor: 4.534

Review 7.  Achieving specificity in Akt signaling in cancer.

Authors:  Alex Toker
Journal:  Adv Biol Regul       Date:  2012-01

8.  The SCFSlimb E3 ligase complex regulates asymmetric division to inhibit neuroblast overgrowth.

Authors:  Song Li; Cheng Wang; Edwin Sandanaraj; Sherry S Y Aw; Chwee T Koe; Jack J L Wong; Fengwei Yu; Beng T Ang; Carol Tang; Hongyan Wang
Journal:  EMBO Rep       Date:  2014-01-10       Impact factor: 8.807

9.  The significance of SUMOylation of angiogenic factors in cancer progression.

Authors:  Mei Wang; Xiaodong Jiang
Journal:  Cancer Biol Ther       Date:  2018-09-27       Impact factor: 4.742

10.  A mechanism for asymmetric cell division resulting in proliferative asynchronicity.

Authors:  Ipsita Dey-Guha; Cleidson P Alves; Albert C Yeh; Xavier Sole; Revati Darp; Sridhar Ramaswamy
Journal:  Mol Cancer Res       Date:  2015-01-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.